Prior exposure to a pyrrolobenzodiazepine or indolino-benzodiazepine based drug, or known hypersensitivity or contraindication to SC-005 or excipient contained in the drug formulation.
History of life-threatening hypersensitivity to monoclonal antibodies or to recombinant proteins or excipients in drug formulation
Patients with a known hypersensitivity to any excipient contained in the drug formulation
Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation, unless undergoing retreatment with rovalpituzumab tesirine in the context of this protocol
Allergic reaction/hypersensitivity to thalidomide or to the excipients contained in the formulation of durvalumab
Known hypersensitivity to any excipient contained in the brentuximab formulation
Patients with known hypersensitivity to any excipient contained in the drug formulation.
Known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation
Hypersensitivity to AQ4N or to any ingredients contained in the drug formulation.
Hypersensitivity to temozolomide or to any ingredients contained in the drug formulation and dacarbazine (DTIC).
Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug or vehicle formulation for margetuximab or pembrolizumab.
Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation, unless undergoing retreatment with rovalpituzumab tesirine in the context of this protocol
Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the drug formulation.
Known or suspected hypersensitivity to the excipients contained in the formulation of durvalumab, lenalidomide, or dexamethasone
Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation.
Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or lenalidomide
Patients with a known hypersensitivity to any excipient contained in the drug
Patients with a known hypersensitivity to any excipient contained in the drug formulation
Prior exposure to a pyrrolobenzodiazepine (PBD)- or indolinobenzodiazepine-based drug, prior participation in a rovalpituzumab tesirine clinical trial, or known hypersensitivity or other contraindications to rovalpituzumab tesirine or excipient contained in the drug formulation.
Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGA271 or pembrolizumab.
Known or suspected hypersensitivity to the excipients contained in the study drug formulation.
Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin or any component of ABVD
Patients with a known hypersensitivity to any excipient contained in the drug formulation
Patients with known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation that includes trehalose, sodium citrate, and polysorbate 80
Known hypersensitivity to recombinant proteins, or any component contained in the drug formulation
Known allergy to any study drug or ingredient contained in the drug formulation of any of the study drugs.
Known hypersensitivity to any excipient contained in the drug formulation of brentuximab vedotin
Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the margetuximab drug formulation
Known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation
Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGD009
Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for enoblituzumab
Prior exposure to a pyrrolobenzodiazepine (PBD)-based drug, or known hypersensitivity to rovalpituzumab tesirine or excipient contained in the drug formulation
